Drug Approval | November 23, 2023
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
The company has raised US$4.5 million in funding for its AI operating system
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
This product will be manufactured at Lupin’s Pithampur facility in India
In 2022, darolutamide was FDA-approved in combination with docetaxel chemotherapy for adults with metastatic hormone-sensitive prostate cancer
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
New Molecular biology lab launched, AIIA increased its work scope in form of MoUs
Subscribe To Our Newsletter & Stay Updated
